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SUMMARY
In a prospective observational study 4485 patients from 46 clinical centres in 17 European countries
were followed between April 1994 and November 1996. Information on AIDS-deﬁning events
(ADEs) were collected together with basic demographic data, treatment history and laboratory
results. The centres were divided into four geographical regions (north, central, south-west and
south-east) so that it was possible to identify any existing regional diﬀerences in ADEs. The
regional diﬀerences that we observed included a higher risk of all forms of Mycobacterium
tuberculosis infections (Tb) and wasting disease in the south-west and an increased risk of infections
with the Mycobacterium avium complex (MAC) in the north. In Cox multivariable analyses, where
north was used as the reference group, we observed hazard ratios of 6.87, 7.77, 2.29 and 0.16
(P<0.05 in all cases) for pulmonary Tb, extrapulmonary Tb, wasting disease and MAC respectively
in the south-west. Pneumocystis carinii pneumonia (PCP) was less commonly diagnosed in the
central region (RH=0.51, 95% CI 0.32–0.79, P=0.003) and most common in the south-east
(RH=1.04, 95% CI 0.71–1.51, P=0.85). Comparisons with a similar ‘AIDS in Europe’ study that
concentrated on the early phase of the epidemic reveal that most of the regional diﬀerences that
were observed in the 1980s still persist in the mid-1990s.
INTRODUCTION
It has previously been shown that there is a regional
variation in the clinical course of HIV resulting in
diﬀerent AIDS-deﬁning events (ADEs) in diﬀerent
areas. For example, Penicillum marneﬀei is a common
opportunistic infection in Thailand [1], cryptococcal
meningitis and cryptosporidiosis are more prevalent
in parts of Africa [2, 3] and histoplasmosis is domi-
nant in southern USA [4]. Co-infection with Tb is
an increasing problem where the micro-organism
Mycobacterium tuberculosis and HIV are common
[5, 6]. Findings of Mycobacterium avium complex
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diﬀerent localities [7].
In the paper ‘Regional Diﬀerences in Presentation
of AIDS in Europe’ we presented retrospective data
on 6578 patients diagnosed with AIDS at 52 clinical
centres in 17 European countries who were followed
between 1979 and 1989 [8, 9]. Diﬀerences in the pres-
entation of AIDS within Europe has also been de-
scribed elsewhere [10]. In our earlier study [8] we
showed some marked diﬀerences: Pneumocystis cari-
nii pneumonia (PCP) was more common in northern
Europe, Kaposi’s sarcoma (KS) and toxoplasmosis
in central Europe, cytomegalovirus chorioretinitis
(CMV retinitis) in south-eastern Europe and extra-
pulmonarytuberculosisinthesouth-west.Theregional
diﬀerencesthatwerepreviouslyobservedstillremained
present after adjustments for potential confounders
such as demography and CD4 count, therefore we
attributed these variations to the diﬀerent degrees of
exposure to the respective underlying pathogens.
In the ongoing, prospective ‘EuroSIDA’ study that
was started in 1994, information is likewise collected
on clinical events, treatment and laboratory ﬁndings.
We were interested in seeing if the regional diﬀerences
that were observed during the early phase of the epi-
demic are still present 10 years later. In the 1990s the
familiarity of diagnosis and treatment of opportun-
istic infections is expected to have increased. During
this time treatment with single or double nucleoside
analogues has also become widespread. We limited
our analysis to the period before highly active anti-
retroviral therapy (HAART), as the introduction of
HAART was associated with a rapid fall in the disease
progressionandmanifestationofADEsamongwestern
patientswithaccesstotreatment[11–13].Fortheover-
whelming majority of patients in the world, and also
forasubstantialnumberofpatientsineconomicallyless
developed regions of Europe, eﬀective anti-retroviral
therapy is still not readily available. The natural
history of HIV/AIDS as it presented before HAART




EuroSIDA is an ongoing prospective, observational
study of 8556 patients with HIV in 63 centres across
Europe (including Israel). Details of the study design
have been published elsewhere [12, 14]. Only the ﬁrst
two cohorts are included in this study. They consist of
4485 patientsfrom 46 centres in 17 countries who were
recruited between April 1994 and June 1996. Eligible
patientswerethoseover16yearsofage,whoattendeda
pre-bookedvisittotheoutpatientclinicandhadaCD4
count of <500 cells/mm
3 within the 4 months preced-
ing recruitment. Consecutive patients from a speciﬁed
starting date were included until a predeﬁned number
of patients had been enrolled in each centre. Baseline
information was collected from patient case notes
and by patient interview onto a standardized data
collection form. Thereafter information on treatment,
clinical condition and laboratory markers was col-
lected every 6 months. The revised CDC deﬁnition for




major centres were visited to ensure correct patient
inclusion and accurate data recording.
Regional demarcation
In order to make regional comparisons within Europe
possible, the continent was, like in the previous study
[8], arbitrarily divided into four regions. The centres
were initially separated into regions using two lati-
tudinal lines. The north consisted of 14 centres
throughout Denmark, Ireland, northern Germany,
The Netherlands, Sweden, Norway, and the United
Kingdom, central contained 12 centres in Austria,
Belgium, France, southern Germany, Luxembourg,
and Switzerland and the remaining centres were
situated in the south. The southern region was fur-
ther divided by a longitudinal line into south-east
(17 centres in Greece, Israel, and Italy) and south-
west (5 centres in Portugal and Spain). Published
data has shown that Tb infections, in particular, are
most common among HIV patients in south-western
Europe, suggesting not only a possible north–south,
but also an east–west diﬀerence in the clinical pre-
sentation of AIDS [9, 16]. A similar longitudinal
division of the north and central regions was not
possible because there was insuﬃcient data from the
eastern parts of these regions within the time period
chosen.
Analysis of AIDS-deﬁning events
The analysis was performed on the 4485 patients who
were recruited between April 1994 and June 1996. The
566 A. Blaxhult and othersTable 1. Demographic details of HIV-positive study patients by region
All centres North Central South-east South-west P value
Number of patients* 4485 1645 1132 1112 596
Gender, no. female (%) 918 (21) 234 (14) 248 (22) 302 (27) 134 (23) <0.001
Age (years) (median, IQR) 35 (31–43) 38 (32–45) 36 (32–44) 33 (30–39) 33 (29–39) <0.001
Transmission category, no. (%)
Homo/bisexual 2069 (46) 1062 (65) 542 (48) 274 (25) 191 (32) <0.001
IDU 1208 (27) 251 (15) 219 (19) 487 (44) 251 (42)
Haemophiliac/blood transfusion 94 (2) 30 (2) 34 (3) 17 (2) 13 (2)
Heterosexual 931 (21) 251 (15) 267 (24) 289 (26) 124 (21)
Other/unknown 183 (4) 51 (3) 70 (6) 45 (4) 17 (3)
Year of being found HIV+
(median, IQR)
1991 (1987–93) 1990 (1986–92) 1991 (1988–93) 1991 (1987–93) 1992 (1989–93) <0.001
Haemoglobin level
(median, IQR)
13.3 (12.0–14.5) 13.2 (12.0–14.5) 13.4 (12.2–14.5) 13.0 (11.7–14.3) 13.3 (11.9–14.4) <0.001
CD4 cell count (cells/mm
3)
(median, IQR)
170 (50–309) 156 (50–288) 170 (52–315) 180 (51–316) 199 (60–340) <0.001
Race, no. (%)
White 4161 (93) 1491 (91) 1038 (92) 1049 (95) 583 (98) <0.001
Asian 39 (1) 24 (1) 10 (1) 5 (0) 0 (0)
Black 248 (6) 107 (7) 80 (7) 52 (5) 9 (2)
Unknown 11 (0) 8 (0) 0 (0) 2 (0) 1 (0)
Weight (kg) (median, IQR) 67 (60–75) 70 (62–78) 67 (59–74) 65 (58–73) 67 (58–75) <0.001
ART naive, no. (%) 1193 (27) 531 (32) 278 (25) 225 (20) 159 (27) <0.001
NRTIs previously used, no. (%)
0 1197 (27) 533 (32) 280 (25) 225 (20) 159 (27) <0.001
1 1608 (36) 596 (36) 315 (28) 498 (45) 199 (33)
2 1338 (30) 412 (25) 380 (34) 345 (31) 201 (34)
3 286 (6) 86 (5) 124 (11) 41 (4) 35 (6)
o4 56 (1) 18 (1) 33 (3) 3 (0) 2 (0)
Previous use of PIs
No. Yes (%) 48 (1) 37 (2) 7 (1) 1 (0) 3 (0) <0.001
Previous use of MAC prophylactic
No. Yes (%) 235 (5) 105 (6) 40 (3) 61 (5) 29 (5) 0.01
Previous use of PCP prophylactics
No. Yes (%) 2349 (52) 897 (55) 572 (51) 532 (48) 348 (58) <0.001




































7baseline demographic data within each region was
examined, where baseline was considered to be the
time of entry into the study. Kruskal–Wallis tests were
used to compare regional diﬀerences for continuous
variables and, depending on the number of obser-
vations, x
2 or Fisher’s exact tests were used to test
frequencies.
The distribution of ADEs experienced before enrol-
ment was examined and is presented as a percentage
of all the patients in the region. A patient was in-
cluded in several categories if they experienced more
than one ADE before entry. Frequencies were again
tested for diﬀerences using x
2 or Fisher’s exact tests.
Prospective analysis was performed on all the
4485 subjects included in this study. All follow-up
information was censored at 1 November 1996, the
date that we assumed HAART had already become
widely used. If HAART, deﬁned as usage of at least
three anti-retroviral drugs, was introduced earlier
than November 1996 then data on these patients
was censored at the date of starting HAART. The
initial ADE that occurred after inclusion and be-
fore November 1996 was investigated using x
2 or
Fisher’s exact tests. A patient was only included in
more than one category if he or she experienced
several ADEs simultaneously. The 16 conditions with
o35 patients suﬀering from them initially was ex-
amined and the number of subjects who experienced
each ADE as their ﬁrst ADE after inclusion is noted
and presented as a percentage of all the subjects in
that region. For most ADEs EuroSIDA did not col-
lect information on recurring conditions or relapses
within the period 1994–6 so only new ADEs were
investigated.
We investigated the incidence rates of each ADE
after enrolment. Since we had no information on re-
curring conditions or relapses, all study subjects who
had previously experienced an ADE were excluded
from the incidence analysis for that speciﬁc ADE. The
incidence analysis compared rates of new ADEs in
subjects with a high CD4 count to subjects with a low
CD4 count. The CD4 count is taken as low the ﬁrst
time that it is <200 cells/mm
3 (not excluding times
when CD4 returned o200 cells/mm
3) therefore sub-
jects were included in the high CD4 count risk set
up to this point. The follow-up time for patients with
a high CD4 count at entry was considered to be
time from enrolment until the ADE, death, a drop in
the CD4 count to below 200 or 1 November 1996
(date of censoring). Similarly, the follow-up time for
patients with a low CD4 count was considered to be
the time from enrolment or a drop in the CD4 count
until the ADE, death or 1 November 1996. If more
than one region had observations in the low and
the high CD4 count strata the rate ratios for these
regions were compared using a Mantel–Haenszel
heterogeneity test. Mantel–Haenszel methods were
again used to calculate an overall rate ratio control-
ling for region to see whether the overall rates of
ADEs in subjects with a low CD4 count were sig-
niﬁcantly diﬀerent to subjects with a high CD4 count.
Incidence rates are presented as 100 person-years of
follow up (PYFU).
Regionaldiﬀerencesintheincidencesofthe16ADEs
with o35 initial diagnoses after enrolment were
analysed using Cox proportional hazard models.
The time parameter was considered to be time from
enrolment until the ADE, death or 1 November 1996,
independent to the CD4 status. The Cox models in-
vestigated all subjects who experienced a speciﬁc ADE
at any time point in the study, not only focusing
on the initial ADE. Cox single variable models were
performed on region, baseline haemoglobin level,
transmission category, gender, age, baseline weight,
race, anti-retroviral naivety at baseline, prophylactic
drug use against MAC (clarithromycin, ethambutol
and rifabutin) and PCP (atovaquone, trimethoprim/
sulphamethoxazole, dapsone and pentamidine), co-
hort, date of being found HIV-infected and baseline
CD4 status (high or low) for each of the ADEs. All
the variables that were signiﬁcant/marginally sig-
niﬁcant (P<0.1) in the single variable analysis were
included in the multivariable models. Variables with
an adjusted hazard ratio that was signiﬁcant at the
5% level (P<0.05) were retained in the ﬁnal model.
Our aim was to investigate regional variations there-
foreregionwasretainedinallthemultivariable models,
irrespective of its signiﬁcance.
RESULTS
Table 1 shows the demographic characteristics of the
HIV-positive patients included in our study for each
region.Transmissionthroughhomosexualcontactwas
more apparent in northern Europe whilst intravenous
drug use was the most common mode of transmission
in southern Europe. There was a greater proportion
of homosexual men in northern Europe and conse-
quently a higher overall percentage of males. Patients
in northern Europe were older at recruitment and
568 A. Blaxhult and othersthey had been known to be HIV positive for a
longertime.Theyhadalsodevelopedamoreprofound
immunodeﬁciency (lower CD4 cell count) at the time
of recruitment compared especially to patients in the
south-west. The proportion who had had previous
treatment with nucleoside analogues varied from 80%
in the south-eastto 68% in the north. Only 48 patients
(1%) had previously been exposed to protease inhibi-
tors. Prophylactic drug use against PCP was com-
monthroughoutEurope:52%ofthepatientshadused
either dapsone, trimethoprim/sulphamethoxazole,
atovaquone or pentamidine before entry whereas
prophylactic drug use against MAC was less frequent.
Only 5% of the patients had used one or more of
rifabutin, clarithromycin or ethambutol before enter-
ing the study. Both MAC and PCP prophylaxis
showed signiﬁcant regional variations throughout
Europe (P=0.01 and P<0.001, respectively).
Table 2 presents data on the frequency of ADEs
before entering the study. Only conditions containing
a total of 40 or more cases are presented. Signiﬁcant
regional diﬀerences were found for 8 of the 17 most
common conditions. In the northern and central re-
gions KS was more common than in other regions. In
the northern region PCP was the dominating AIDS-
deﬁning condition whilst this was relatively uncom-
mon in the south-west. Tb was most common in the
south-west region while MAC was more common
in the north and central regions. None of the less
common ADEs reached any statistically signiﬁcant
diﬀerences except candida pneumonia where 10 of
11 registered cases originated from the south-east
(P<0.001).
Table 2 also shows the ﬁrst ADE presenting after
inclusion into the study. Only the 16 conditions with
at least 35 events are shown. Mycobacterium tubercu-
losis and wasting disease were most prevalent in the
south-west, KS was most commonly found in the
central and northern regions whilst PCP was most
widespread in the north and south-east. After oeso-
phageal candidiasis, the second most frequently diag-
nosed disease in the north was MAC whereas in the
south-east it was AIDS dementia complex. The north
contained 75 initial cases of MAC, corresponding to
13.4% of all the patients in the north who experienced
an ADE after inclusion. This is signiﬁcantly more
than in any other region of Europe. In the south-east
nearly double the proportion of subjects had AIDS
dementia complex as their ﬁrst ADE compared to
those in the north. Among the ADEs with fewer
events only cryptococcal meningitis showed a regional
tendency. Of 26 cases in total 13 were found in the
south-east (P value=0.03).
Incidence data for the major ADEs in Table 3 show
some diﬀerences between the regions. Most striking
is the high incidence of Tb in the south-west where
subjects with a CD4 count <200 cells/mm
3 had an
incidence of 3.5 per 100 PYFU and subjects with a
CD4 count o200 had an incidence of 2.4/100 PYFU.
There was a noticeably higher incidence of AIDS de-
mentia complex in the south-east compared to other
regions where subjects with a CD4 count <200 cells/
mm
3 were most at risk. These subjects had an inci-
dence of 4.1/100 PYFU whereas the subjects with
higher CD4 counts had an incidence of 0.9/100
PYFU. Subjects from southern Europe were also
marginally (P=0.075) more at risk from wasting than
patients from either northern or central Europe. The
overall rates of wasting for patients from the south-
east and south-west were 3.0 and 3.6 per 100 PYFU,
respectively, whereas in the north and central regions
these rates were only 2.1a n d1 .5 per 100 PYFU,
respectively. The combined rate ratios showed sig-
niﬁcantly diﬀerent rates of disease between patients
with high and low CD4 counts for most of the major
ADEs, the main exceptions were recurrent bacterial
pneumonia in addition to pulmonary and extrapul-
monary Tb.
Cox analysis was performed on the ADEs that
occurred during follow up (Table 4). AIDS dementia
complex, recurrent bacterial pneumonia, wasting
disease, MAC, Tb (both pulmonary and extrapul-
monary), PCP and KS were all shown to vary be-
tween regions in the single variable analysis. After
adjustments were made for confounding factors that
were signiﬁcant at the 5% level most of the regional
variations still remained. Region was, however, no
longer a signiﬁcant predictor of the hazard of de-
veloping KS.
DISCUSSION
The data that we have presented shows evident dif-
ferences in ADEs within diﬀerent regions of Europe
in the mid-1990s. Tb continues to be a problem in the
south-west and MAC in the north. The epidemiology
of these particular pathogens have been described in
more detail elsewhere [17].
Before inclusion to the study Pulmonary Tb was
diagnosed in 11.9% (32.6% of all patients with an
ADE) and extrapulmonary Tb infections in 8.2%
AIDS in European regions before HAART 569Table 2. Distributions of diagnosis of ADEs before enrolment and of primary diagnoses of ADEs after enrolment
AIDS-deﬁning
conditions*
Before enrolment Primary diagnoses after enrolment









Number of patients 4485 1645 1132 1112 596 4485 1645 1132 1112 596
AIDS dementia
complex
65 (1.4) 29 (1.8) 15 (1.3) 13 (1.2) 8 (1.3) 0.59 102 (2.3) 35 (2.1) 18 (1.6) 44 (4.0) 5 (0.8) <0.001
Recurrent bacterial
pneumonia
53 (1.2) 19 (1.2) 14 (1.2) 12 (1.1) 8 (1.3) 0.97 62 (1.4) 26 (1.6) 16 (1.4) 18 (1.6) 2 (0.3) 0.20
Oesophageal
candidiasis
365 (8.1) 148 (9.0) 87 (7.7) 77 (6.9) 53 (8.9) 0.21 210 (4.7) 92 (5.6) 48 (4.2) 53 (4.8) 17 (2.9) 0.37
Cryptococcal
meningitis
46 (1.0) 13 (0.8) 13 (1.1) 12 (1.1) 8 (1.3) 0.6 4 ———— — —
Cryptosporidosis 70 (1.6) 25 (1.5) 16 (1.4) 21 (1.9) 8 (1.3) 0.77 40 (0.9) 16 (1.0) 8 (0.7) 14 (1.3) 2 (0.3) 0.34
CMV retinitis 141 (3.1) 57 (3.5) 27 (2.4) 42 (3.8) 15 (2.5) 0.18 119 (2.7) 45 (2.7) 32 (2.8) 28 (2.5) 14 (2.3) 0.69
CMV in another
location
43 (1.0) 24 (1.5) 7 (0.6) 6 (0.5) 6 (1.0) 0.05 84 (1.9) 32 (1.9) 20 (1.8) 22 (2.0) 10 (1.7) 0.96
HSV ulcers 78 (1.7) 41 (2.5) 15 (1.3) 14 (1.3) 8 (1.3) 0.03 64 (1.4) 22 (1.3) 20 (1.8) 17 (1.5) 5 (0.8) 0.28
HIV wasting
syndrome
85 (1.9) 28 (1.7) 27 (2.4) 21 (1.9) 9 (1.5) 0.52 106 (2.4) 37 (2.2) 18 (1.6) 28 (2.5) 23 (3.9) 0.005
Microsporidosis
with wasting
49 (1.1) 28 (1.7) 18 (1.6) 2 (0.2) 1 (0.2) <0.001 — — — — — —
Mycobact. avium
complex
124 (2.8) 72 (4.4) 27 (2.4) 20 (1.8) 5 (0.8) <0.001 111 (2.5) 75 (4.6) 20 (1.8) 11 (1.0) 5 (0.8) <0.001
Mycobact.
tuberculosis
164 (3.7) 25 (1.5) 33 (2.9) 35 (3.1) 71 (11.9) <0.001 44 (1.0) 6 (0.4) 8 (0.7) 10 (0.9) 20 (3.4) <0.001
EPMT 111 (2.5) 16 (1.0) 25 (2.2) 21 (1.9) 49 (8.2) <0.001 42 (0.9) 9 (0.5) 3 (0.3) 6 (0.5) 24 (4.0) <0.001
PCP 506 (11.3) 235 (14.3) 108 (9.5) 114 (10.3) 49 (8.2) <0.001 142 (3.2) 69 (4.2) 19 (1.7) 39 (3.5) 15 (2.5) 0.032
P M L ———— — — 3 9 ( 0 .9) 13 (0.8) 14 (1.2) 10 (0.9) 2 (0.3) 0.16
Cerebral
toxoplasmosis
120 (2.7) 48 (2.9) 35 (3.1) 25 (2.2) 12 (2.0) 0.41 67 (1.5) 24 (1.5) 20 (1.8) 16 (1.4) 7 (1.2) 0.53
Kaposi’s sarcoma 334 (7.4) 170 (10.3) 93 (8.2) 45 (4.0) 26 (4.4) <0.001 114 (2.5) 57 (3.5) 36 (3.2) 13 (1.2) 8 (1.3) <0.001
Non-Hodgkin
lymphoma
40 (0.9) 13 (0.8) 15 (1.3) 5 (0.4) 7 (1.2) 0.13 67 (1.5) 28 (1.7) 17 (1.5) 13 (1.2) 9 (1.5) 0.72
Other ADE 80 (1.8) 20 (1.2) 19 (1.7) 28 (2.5) 13 (2.2) 0.07 75 (1.7) 17 (1.0) 12 (1.1) 32 (2.9) 14 (2.3) <0.001
No ADE 2970 (66.2) 1039 (63.2) 773 (68.3) 780 (70.1) 378 (63.4) <0.001 3121 (69.6) 1087 (66.1) 824 (72.8) 772 (69.4) 438 (73.5) <0.001
Percentage of subjects with each ADE is given in parentheses.
* ADE, AIDS-deﬁning event; CMV, cytomegalovirus chorioretinitis; HSV, herpes simplex virus; EPMT, extrapulmonary Mycobacterium tuberculosis; PCP, Pneumocystis































o200 7 0.9( 0 .4–1.8) 0.3( 0 .0–2.1) 1.8( 0 .6–5.7) 0.9( 0 .2–3.7) 1.1( 0 .2–8.1)
<200 150 2.4( 2 .0–2.8) 2.6( 2 .0–3.3) 1.3( 0 .8–1.9) 4.1( 3 .2–5.3) 1.0( 0 .5–1.9)
Overall 157 2.2( 1 .9–2.6) 2.3( 1 .8–3.0) 1.3( 0 .9–2.0) 3.7( 2 .9–4.7) 1.0( 0 .5–1.9) 0.022
Recurrent bacterial pneumonia
o200 8 1.0( 0 .5–2.0) 1.2( 0 .4–3.1) 0.6( 0 .1–4.3) 1.4( 0 .4–4.3) —
<200 74 1.2( 0 .9–1.5) 1.5( 1 .1–2.1) 1.0( 0 .6–1.5) 1.4( 1 .0–2.2) 0.2( 0 .1–1.0)
Overall 82 1.2( 0 .9–1.4) 1.5( 1 .1–2.0) 0.9( 0 .6–1.5) 1.4( 1 .0–2.1) 0.2( 0 .1–0.9) 0.96
Cryptosporidiosis
o200 1 0.1( 0 .0–0.9) — — 0.5( 0 .1–3.3) —
<200 59 0.9( 0 .7–1.2) 0.8( 0 .5–1.3) 0.8( 0 .5–1.4) 1.3( 0 .9–2.1) 0.7( 0 .3–1.6)
Overall 60 0.8( 0 .7–1.1) 0.7( 0 .5–1.2) 0.7( 0 .4–1.3) 1.2( 0 .8–1.9) 0.6( 0 .3–1.4) 0.65
CMV
o200 1 0.1( 0 .0–0.9) 0.3( 0 .0–2.1) — — —
<200 239 3.9( 3 .4–4.4) 4.6( 3 .7–5.5) 3.3( 2 .5–4.3) 3.9( 3 .0–5.1) 3.3( 2 .3–4.8)
Overall 240 3.4( 3 .0–3.9) 4.0( 3 .3–4.8) 3.0( 2 .3–3.9) 3.4( 2 .6–4.4) 3.0( 2 .0–4.3) 0.78
CMV in another location
o200 2 0.2( 0 .1–1.0) 0.3( 0 .0–2.1) — 0.5( 0 .1–3.3) —
<200 154 2.4( 2 .1–2.8) 2.7( 2 .1–3.4) 2.3( 1 .7–3.2) 2.5( 1 .8–3.4) 1.9( 1 .2–3.1)
Overall 156 2.2( 1 .9–2.6) 2.4( 1 .8–3.0) 2.1( 1 .6–2.9) 2.2( 1 .6–3.1) 1.7( 1 .1–2.8) 0.81
HIV wasting syndrome
o200 4 0.5( 0 .2–1.3) — 1.2( 0 .3–4.8) 0.9( 0 .2–3.7) —
<200 162 2.6( 2 .2–3.0) 2.4( 1 .8–3.1) 1.5( 1 .0–2.2) 3.3( 2 .5–4.4) 4.0( 2 .8–5.6)
Overall 166 2.3( 2 .0–2.7) 2.1( 1 .6–2.7) 1.5( 1 .0–2.2) 3.0( 2 .3–3.9) 3.6( 2 .6–5.1) 0.075
Mycobact. avium complex
o200 2 0.2( 0 .1–1.0) 0.3( 0 .0–2.1) 0.6( 0 .1–4.3) — —
<200 191 3.1( 2 .7–3.5) 5.0( 4 .2–6.1) 2.7( 2 .1–3.7) 1.8( 1 .2–2.6) 1.1( 0 .6–2.1)
Overall 193 2.8( 2 .4–3.2) 4.4( 3 .6–5.3) 2.5( 1 .9–3.4) 1.6( 1 .1–2.3) 1.0( 0 .5–1.9) 0.65
Mycobacterium tuberculosis
o200 8 1.0( 0 .5–2.0) 0.6( 0 .1–2.4) 2.4( 0 .9–6.3) — 2.4( 0 .6–9.5)
<200 56 0.9( 0 .7–1.2) 0.4( 0 .2–0.8) 0.4( 0 .2–0.8) 0.9( 0 .6–1.6) 3.5( 2 .4–5.1)
Overall 64 0.9( 0 .7–1.2) 0.5( 0 .3–0.8) 0.5( 0 .3–1.0) 0.8( 0 .5–1.4) 3.4( 2 .3–4.9) 0.006
Extrapulm. Mycobact. tuberculosis
o200 5 0.6( 0 .3–1.5) 0.3( 0 .0–2.1) — 0.5( 0 .1–3.3) 3.5( 1 .1–10.8)
<200 48 0.8( 0 .6–1.0) 0.5( 0 .3–0.9) 0.2( 0 .1–0.6) 0.4( 0 .2–0.9) 3.3( 2 .3–4.9)
Overall 53 0.7( 0 .6–1.0) 0.5( 0 .3–0.9) 0.2( 0 .1–0.6) 0.4( 0 .2–0.8) 3.4( 2 .3–4.8) 0.88
PCP
o200 7 0.9( 0 .4–1.9) 0.9( 0 .3–2.8) 0.6( 0 .1–4.4) 0.9( 0 .2–3.8) 1.2( 0 .2–8.3)
<200 181 3.1( 2 .7–3.6) 4.1( 3 .3–5.1) 1.7( 1 .2–2.5) 3.9( 3 .0–5.1) 2.4( 1 .5–3.8)
Overall 188 2.9( 2 .5–3.3) 3.6( 2 .9–4.5) 1.6( 1 .1–2.3) 3.5( 2 .7–4.5) 2.3( 1 .5–3.5) 0.90
PML
o200 0 — — — — —
<200 58 0.9( 0 .7–1.2) 1.0( 0 .7–1.6) 1.0( 0 .7–1.6) 0.8( 0 .4–1.4) 0.5( 0 .2–1.3)
Overall 58 0.8( 0 .6–1.0) 0.9( 0 .6–1.4) 0.9( 0 .6–1.5) 0.7( 0 .4–1.2) 0.4( 0 .2–1.1) —
Cerebral toxoplasmosis
o200 1 0.1( 0 .0–0.9) — — 0.5( 0 .1–3.3) —
<200 108 1.7( 1 .4–2.1) 1.8( 1 .4–2.5) 1.7( 1 .2–2.5) 1.7( 1 .2–2.5) 1.4( 0 .8–2.5)
Overall 109 1.5( 1 .3–1.9) 1.6( 1 .2–2.2) 1.6( 1 .1–2.3) 1.6( 1 .1–2.3) 1.3( 0 .7–2.3) 0.44
Kaposi’s sarcoma
o200 7 0.9( 0 .4–1.8) 1.5( 0 .6–3.6) 0.6( 0 .1–4.3) 0.5( 0 .1–3.3) —
<200 140 2.4( 2 .0–2.8) 3.5( 2 .7–4.4) 3.0( 2 .2–4.0) 0.8( 0 .5–1.4) 1.4( 0 .8–2.5)
Overall 147 2.2( 1 .9–2.6) 3.2( 2 .5–4.0) 2.8( 2 .1–3.7) 0.8( 0 .4–1.3) 1.2( 0 .7–2.2) 0.77
Non-Hodgkin lymphoma
o200 5 0.6( 0 .3–1.5) 0.3( 0 .0–2.1) 0.6( 0 .1–4.4) 1.4( 0 .4–4.2) —
<200 110 1.7( 1 .4–2.1) 2.3( 1 .8–3.1) 1.3( 0 .9–2.0) 1.4( 0 .9–2.2) 1.4( 0 .8–2.5)
Overall 115 1.6( 1 .3–1.9) 2.1( 1 .6–2.7) 1.3( 0 .9–1.9) 1.4( 1 .0–2.1) 1.3( 0 .7–2.3) 0.21
Signiﬁcantly diﬀerent incidence rate between patients with a high CD4 count and a low CD4 count were seen. P<0.01 in all cases except
recurrent bacterial pneumonia (P=0.527), cryptosporidiosis (P=0.017), Mycobacterium tuberculosis (P=0.71), extrapulmonary
Mycobacterium tuberculosis (P=0.72) and non-Hodgkin lymphoma (P=0.015).
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AIDS dementia complex <0.001 0.002
North 1.00 — — 1.00 — —
Central 0.59 0.37–0.95 0.03 0.69 0.42–1.14 0.15
South-east 1.64 1.15–2.34 0.01 1.44 0.94–2.21 0.10
South-west 0.43 0.21–0.86 0.02 0.37 0.13–1.03 0.06
Recurrent bacterial pneumonia <0.001 0.01
North 1.00 — — 1.00 — —
Central 0.63 0.36–1.12 0.12 0.67 0.36–1.23 0.20
South-east 1.00 0.60–1.65 0.99 0.70 0.38–1.28 0.25
South-west 0.15 0.04–0.61 0.01 0.16 0.04–0.68 0.01
Oesophageal candidiasis 0.12 0.45
North 1.00 — — 1.00 — —
Central 0.80 0.59–1.07 0.13 0.81 0.60–1.11 0.20
South-east 0.82 0.61–1.11 0.20 0.82 0.59–1.14 0.24
South-west 0.65 0.43–0.97 0.04 0.79 0.52–1.22 0.29
Cryptosporoidosis 0.29 0.008
North 1.00 — — 1.00 — —
Central 1.06 0.53–2.12 0.87 1.34 0.67–2.70 0.41
South-east 1.71 0.92–3.18 0.09 3.20 1.65–6.23 <0.001
South-west 0.89 0.36–2.24 0.81 1.43 0.56–3.62 0.45
CMV chorioretinitis 0.35 0.26
North 1.00 — — 1.00 — —
Central 0.77 0.55–1.07 0.12 0.74 0.51–1.07 0.11
South-east 0.87 0.63–1.21 0.41 1.11 0.75–1.63 0.61
South-west 0.75 0.49–1.15 0.19 0.95 0.58–1.54 0.83
CMV in another location 0.71 0.71
North 1.00 — — 1.00 — —
Central 0.91 0.61–1.36 0.65 1.16 0.75–1.80 0.50
South-east 0.96 0.64–1.43 0.84 1.33 0.82–2.16 0.24
South-west 0.73 0.42–1.27 0.27 1.14 0.64–2.03 0.65
Herpes simplex virus ulcers 0.05 0.06
North 1.00 — — 1.00 — —
Central 1.51 0.91–2.51 0.11 1.63 0.97–2.74 0.06
South-east 0.99 0.55–1.76 0.96 1.07 0.59–1.95 0.82
South-west 0.48 0.18–1.23 0.13 0.56 0.21–1.45 0.23
Wasting disease <0.001 <0.001
North 1.00 — — 1.00 — —
Central 0.74 0.47–1.17 0.20 0.63 0.37–1.08 0.09
South-east 1.48 1.01–2.18 0.04 1.50 0.94–2.39 0.09
South-west 1.76 1.14–2.72 0.01 2.29 1.33–3.95 0.003
Mycobacterium avium complex <0.001 <0.001
North 1.00 — — 1.00 — —
Central 0.59 0.42–0.83 <0.001 0.57 0.39–0.83 <0.001
South-east 0.36 0.24–0.55 <0.001 0.41 0.25–0.68 <0.001
South-west 0.22 0.11–0.44 <0.001 0.16 0.05–0.52 <0.001
Pulmonary tuberculosis <0.001 <0.001
North 1.00 — — 1.00 — —
Central 1.19 0.51–2.76 0.68 0.92 0.38–2.25 0.86
South-east 1.78 0.83–3.86 0.14 1.62 0.74–3.58 0.23
South-west 7.41 3.76–14.56 <0.001 6.87 3.46–13.63 <0.001
572 A. Blaxhult and others(22.5% of all patients with an ADE) of the patients
in the south-west. Furthermore, during follow-up
pulmonary and extrapulmonary Tb infections were,
together with wasting disease, the dominating ADEs
in this region (in the south-west 12.7 and 15.2% of the
initial ADEs after inclusion were due to pulmonary
Tb and extrapulmonary Tb, respectively). It is poss-
ible that among the patients with wasting disease
there may also be cases of undiagnosed Tb. In the
previous AIDS in Europe study [18] extrapulmonary
Tb accounted for over 35% of the AIDS cases in the
south-west [8] in addition more pronounced regional
diﬀerences were seen. Only extrapulmonary Tb was
regarded as an ADE at the time, which makes com-
parisons with the present study diﬃcult. It seems,
however that Tb accounted for a larger proportion of
ADEs at that time. A fall in Tb has also been noted in
other studies [19].
PCP was diagnosed in only 11% of the patients at
inclusion to this study. PCP, however, accounts for
33.3% of the 1515 patients who experienced at least
one ADE prior to entering the study. More remark-
ably, among 1364 patients who developed an ADE
during follow-up only 10.4% of events are due to
PCP. As a comparison PCP accounted for 38.5% of
initial diagnosis of AIDS 10 years earlier [8]. This fall
can be a consequence of increased use of primary
prophylactic antibiotics. There is a regional diﬀerence
for PCP with fewest cases in the central region. The
incidence for PCP here is lower both for patients with
Table 4 (cont.)











Extrapulmonary tuberculosis <0.001 <0.001
North 1.00 — — 1.00 — —
Central 0.45 0.15–1.38 0.16 0.37 0.10–1.33 0.13
South-east 0.83 0.33–2.08 0.69 0.62 0.22–1.80 0.38
South-west 6.74 3.50–12.96 <0.001 7.77 3.84–15.73 <0.001
PCP <0.001 0.005
North 1.00 — — 1.00 — —
Central 0.45 0.29–0.69 <0.001 0.51 0.32–0.79 0.003
South-east 0.98 0.70–1.38 0.91 1.04 0.71–1.51 0.85
South-west 0.63 0.39–1.03 0.07 0.69 0.41–1.16 0.16
PML 0.36 0.19
North 1.00 — — 1.00 — —
Central 1.04 0.56–1.91 0.91 1.28 0.67–2.45 0.45
South-east 0.75 0.37–1.50 0.41 0.80 0.37–1.72 0.57
South-west 0.46 0.16–1.33 0.15 0.41 0.12–1.38 0.15
Cerebral toxoplasmosis 0.94 0.88
North 1.00 — — 1.00 — —
Central 1.00 0.62–1.61 1.00 1.02 0.61–1.70 0.94
South-east 0.99 0.61–1.62 0.98 0.91 0.52–1.59 0.74
South-west 0.83 0.43–1.57 0.56 0.77 0.37–1.60 0.48
Kaposi’s sarcoma <0.001 0.12
North 1.00 — — 1.00 — —
Central 0.88 0.61–1.27 0.50 1.11 0.75–1.65 0.60
South-east 0.24 0.13–0.44 <0.001 0.55 0.29–1.05 0.07
South-west 0.39 0.20–0.73 <0.001 0.72 0.37–1.42 0.34
Non-Hodgkin lymphoma 0.15 0.68
North 1.00 — — 1.00 — —
Central 0.63 0.39–1.01 0.06 0.67 0.39–1.15 0.15
South-east 0.70 0.43–1.11 0.13 0.84 0.47–1.51 0.56
South-west 0.62 0.33–1.16 0.13 0.92 0.48–1.77 0.80
* CMV, cytomegalovirus; PCP, Pneumocystis carinii pneumonia; PML, progressive multifocal leucoencephalopathy.
AIDS in European regions before HAART 573a CD4 count of above and below 200. In the AIDS
in Europe study there was also a regional diﬀerence in
PCP, but in contrast to this present study the north
previously had the highest incidence and the south-
west had the lowest. Factors behind that ﬁnding have
been analysed by Lundgren [20]. Further studies are
needed to explain this changing pattern.
KS accounted for 21% of AIDS registrations in
patients studied in the 1980s. In this study 7.4% of
patients had had KS at inclusion (accounting for
22.0% of patients with at least one ADE at inclusion).
Only 8.4% of the ADEs that developed during
follow up were KS. A fall in PCP and KS during
the time period has also been seen among Italian and
Australian AIDS patients [21, 22]. KS continues to
be more common in northern and central Europe,
however in the multivariable analysis other factors
than region per se are now shown to be of greater
importance.
Unlike in the previous study, CMV retinitis, toxo-
plasmosis and lymphomas did not show any clear
regional diﬀerences. One explanation could be that
diagnostic procedures and therapies have become
more uniform within Europe.
When interpreting the data some factors must be
kept in mind. The demographic characteristics of the
patients studied in the two time periods are diﬀerent.
In the 1980s study the intravenous drug users con-
stituted around 60% of the patients from southern
Europe while this percentage has fallen to just over
40% in this study. The selection of patients was also
diﬀerent in the two studies. In the retrospective
‘AIDS in Europe’ study all the patients had already
developed AIDS and some were even deceased at
inclusion. In this prospective EuroSIDA study the
patients have to present themselves at a pre-booked
appointment in order to be recruited. Due to changes
in the epidemic the percentage of women in the study
has increased from 9 to 21%. Patients in the north
continue to be the oldest at time of HIV diagnosis
but this diﬀerence is less pronounced than 10 years
earlier.
Survival in southern Europe was shorter in the
patients studied in the 1980s [9], limiting the occur-
rence of ADEs associated with advanced HIV infec-
tion.Inthisstudy83%ofthepatientshadcommenced
therapywithnucleosideanalogues.Thistreatmentcan,
however only be expected to postpone disease [23–29].
The introduction of HAART changed the distri-
bution of ADEs in Europe [13]. In the present study,
however, very few patients had commenced on any
proteaseinhibitorcontainingtherapy duetocensoring
at initiation of HAART or late 1996.
In summary, major regional diﬀerences in the risk
of developing important ADEs such as Tb and PCP
remain. Minor diﬀerences were also seen for AIDS
dementia complex and wasting syndrome. These
clinically deﬁned conditions were diagnosed at sig-
niﬁcantly diﬀerent CD4 levels between regions which
may inﬂuence the reported incidence. The earlier de-
scribed regional diﬀerences in toxoplasmosis, CMV
retinitis, and KS are less evident in this study. The
number of events is relatively small which in itself
makes it statistically diﬃcult to show diﬀerences. If
there is a true change this can, for KS, be due to a
regionally more similar exposure to underlying co-
infections [30–32]. The regional diﬀerences reported
in this study are likely to reﬂect true diﬀerences in
the occurrence of the pathogens, though we cannot
deﬁnitely exclude the possibility of diﬀerences in
diagnostic procedures explaining at least part of the
regional diﬀerences.
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APPENDIX
The multicentre study group on EuroSIDA (national
co-ordinators in parentheses). Austria: (N. Vetter)
Pulmologisches Zentrum der Stadt Wien, Vienna.
Belgium: (N. Clumeck), P. Hermans, B. Sommereijns,
Saint-Pierre Hospital, Brussels; R. Colebunders, In-
stituteofTropicalMedicine,Antwerp.CzechRepublic:
(L.Machala),H.Rozsypal,FacultyHospitalBulovka,
Prague. Denmark: (J. Nielsen), J. Lundgren, T. Ben-
ﬁeld, O. Kirk, Hvidovre Hospital, Copenhagen; J.
Gerstoft, T. Katzenstein, B. Røge, P. Skinhøj, Rig-
shospitalet, Copenhagen; C. Pedersen, Odense Uni-
versityHospital,Odense.Estonia:(K.Zilmer),Tallinn
574 A. Blaxhult and othersMerimetsaHospital,Tallinn.France:(C.Katlama),M.
DeSa,Ho ˆ pitaldelaPitie ´ -Salpe ´ tie ` re,Paris;J.-P.Viard,
Ho ˆ pital Necker-Enfants Malades, Paris; T. Saint-
Marc, Ho ˆ pital Edouard Herriot, Lyon; P. Vanhems,
University Claude Bernard, Lyon;C. Pradier,Ho ˆ pital
de l’Archet, Nice. Germany: (M. Dietrich), C. Mane-
gold, Bernhard-Nocht-Institut for Tropical Medicine,
Hamburg; J. van Lunzen, H.-J. Stellbrink, Eppendorf
Medizinische Kernklinik, Hamburg; V. Miller, S.
Staszewski, J. W. Goethe University Hospital, Frank-
furt; F.-D. Goebel, Medizinische Poliklinik, Munich;
B. Salzberger, Universita ¨ tK o ¨ ln, Cologne; J. Rock-
stroh,Universita ¨ tsKlinikBonn.Greece:(J.Kosmidis),
P. Gargalianos, H. Sambatakou, J. Perdios, Athens
General Hospital, Athens; G. Panos, I. Karydis, A.
Filandras, 1st IKA Hospital, Athens. Hungary: (D.
Banhegyi), S. La ´ slo ´ Hospital, Budapest. Ireland:
(F. Mulcahy), St James’s Hospital, Dublin. Israel:
(I. Yust), M. Burke, Ichilov Hospital, Tel Aviv; S.
Pollack,Z.Ben-Ishai,RambamMedicalCenter,Haifa;
Z. Bentwich, Kaplan Hospital, Rehovot; S. Maayan,
Hadassah University Hospital, Jerusalem. Italy: (S.
Vella, A. Chiesi), Istituto Superiore di Sanita, Rome;
C. Arici, Ospedale Riuniti, Bergamo; R. Pristera ´ ,
Ospedale Generale Regionale, Bolzano; F. Mazzotta,
A.Gabbuti,OspedaleS.MariaAnnunziata,Florence;
R.Esposito,A.Bedini,Universita ` diModena,Modena;
A. Chirianni, E. Montesarchio, Presidio Ospedaliero
A.D. Cotugno, Naples; V. Vullo, P. Santopadre, Uni-
versita ` di Roma La Sapienza, Rome; P. Narciso, A.
Antinori, P. Franci, M. Zaccarelli, Ospedale Spallan-
zani, Rome; A. Lazzarin, R. Finazzi, Ospedale San
Raﬀaele, Milan; A. D’Arminio Monforte, Osp. L.
Sacco,Milan.Latvia:(L.Viksna),InfectologyCentreof
Latvia, Riga. Lithuania: (S. Chaplinskas), Lithuanian
AIDS Centre, Vilnius. Luxembourg: (R. Hemmer), T.
Staub, Centre Hospitalier, Luxembourg. The Nether-
lands: (P. Reiss), Academisch Medisch Centrum bij de
Universiteit van Amsterdam, Amsterdam. Norway:
(J.Bruun),A.Maeland,V.Ormaasen,Ulleva ˚ lHospital,
Oslo. Poland: (B. Knysz), J. Gasiorowski, Medical
University, Wroclaw; A. Horban, Centrum Diagnos-
tyki i Terapii AIDS, Warsaw; D. Prokopowicz, A.
Wiercinska-Drapalo, Medical University, Bialystok;
A.Boron-Kaczmarska,M.Pynka,MedicalUniversity,
Szczecin; M. Beniowski, Osrodek Diagnostyki i
Terapii AIDS, Chorzow; H. Trocha, Medical Uni-
versity, Gdansk. Portugal: (F. Antunes), Hospital
Santa Maria, Lisbon; K. Mansinho, Hospital de Egas
Moniz, Lisbon; R. Proenca, Hospital Curry Cabral,
Lisbon. Romania: A. Streinu-Cercel, Institute of
Infectious Diseases ‘Prof. Dr Matei Bals’, D. Duicu-
lescu,SpitaluldeBoliInfectioasesiTropicaleDrVictor
Babes. Slovakia: (M. Mikras), Derrer Hospital, Bra-
tislava.Spain:(J.Gonza ´ lez-Lahoz),B.Diaz,T.Garcı´a-
Benayas, L. Martin-Carbonero, V. Soriano, Hospital
Carlos III, Madrid; B. Clotet, A. Jou, J. Conejero, C.
Tural, Hospital Germans Trias i Pujol, Badalona;
J. M. Gatell, J. M. Miro ´ , Hospital Clinic i Provincial,
Barcelona. Sweden: (A. Blaxhult), Karolinska Hospi-
tal, Stockholm; A. Karlsson, So ¨ dersjukhuset, Stock-
holm; P. Pehrson, Huddinge Sjukhus, Stockholm.
Switzerland: (B. Ledergerber), R. Weber, University
Hospital,Zu ¨ rich;P.Francioli,A.Telenti,CentreHos-
pitalier Universitaire Vaudois, Lausanne; B. Hirschel,
V. Soravia-Dunand, Hospital Cantonal Universitaire
de Geneve, Geneve. United Kingdom: (S. Barton) St
Stephen’s Clinic, Chelsea and Westminster Hospital,
London; A. M. Johnson, D. Mercey, Royal Free and
University College London Medical School, London
(UniversityCollegeCampus);A.Phillips,C.Loveday,
M. A. Johnson, A Mocroft, Royal Free and Univer-
sity College Medical School, London (Royal Free
Campus); A. Pinching, J. Parkin, Medical College
of St Bartholomew’s Hospital, London; J. Weber,
G. Scullard, Imperial College School of Medicine at
St Mary’s, London; M. Fisher, Royal Sussex County
Hospital, Brighton; R. Brettle, Western General Hos-
pital,Edinburgh.Virologygroup:C.Loveday,B.Clotet
(Central Coordinators) plus ad hoc virologists from
participating sites in the EuroSIDA Study. Steering
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